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Abstract 
 
During last decade, human fungal diseases gained importance as few pathogens cause life-threatening 
infections and Candida albicans is one among them. The recent antifungal resistance exhibited by C.albicans and 
other related fungi demand new drugs. Since natural products are potent source of antimicrobial compounds, an 
attempt was made using two terpenoids, viz.,  1-2, 4, 5- Tri Methoxy Phenyl -1'- Methoxy Propionaldehyde 
(TMPMP) and 1-2, 4, 5- Tri Methoxy Acetophenone (TMAP), extracted from traditional Indian medicinal plant, 
Acorus calamus for its antifungal efficacy. The present study demonstrates the efficacy of these two terpenoids by 
exploring their effect on the virulence factors of the chosen organism. Results reveal the major virulence factors, 
namely, acidic, alkaline and neutral proteases, secreted aspartyl protease, lipase, phospholipase, elastase and 
keratinase activities have been completely reduced in the presence of TMPMP and TMAP compared to control. 
The reduction in virulence factors was on par with standard antifungal drug Fluconazole.  
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1. Introduction 
 
Candida albicans, an opportunistic 
fungal pathogen can cause either systemic or 
mucosal infections in humans. In 
immunocompromised patients, Candida 
infections may lead to life-threatening 
circumstances [1, 2]. Recent reports claim that 
C. albicans accounts for 72% of nosocomial 
fungal infections and have surpassed Gram 
negative bacteria and as third most frequently 
isolated organism from bloodstream infections 
[3].  
Increased incidence of invasive 
mycoses and emerging problems of antifungal 
drug resistance have encouraged the search for 
new antifungal drugs. Present day therapeutic 
options are limited to three major classes of 
compounds namely, polyenes, azoles, and 
candins [4, 5]. Utility of polyenes are limited by 
their nephrotoxicity [6]. Though azoles are 
relatively safer, the cross-resistance exhibited by 
fungal species restricts their usage. Later, during 
2001, echinocandins - a lipopeptide with high 
fungicidal activity and negligible toxicities was 
introduced. Within four years, in vitro 
echinocandin resistance, along with cross-
resistance to other echinocandins, is reported by 
Moudgal et al., [7]. Ghannoum et al., [8] 
reported during the past decade considerable 
increase in the emergence of antifungal 
resistance had implication on morbidity, 
mortality, and health care, and thus demands 
new, safe, and more efficacious antifungal drugs. 
Despite the existing synthetic drugs, 
natural products have always been a choice for 
potent antimicrobial source. Antifungal efficacy 
of plant derived antimicrobial compounds is 
reported by number of researchers [9-14] and the 
antifungal efficacy of terpenoids is reported by 
[15]. In our preliminary studies we found, 
methanolic extracts and unidentified active 
fractions exhibited antidermatophytic as well as 
anticandidal properties [16, 17]. In the present 
study, an attempt was made on the evaluation of 
anticandidal efficacy of novel terpenoids 1-2, 4, 
5- Trimethoxy phenyl -1'- methoxy 
propionaldehyde (TMPMP) and 1-2, 4, 5- 
Trimethoxy acetophenone (TMAP) isolated from 
rhizomes of A.calamus L (The extraction 
procedures and the structural elucidation based 
on physico-chemical characterization of these 
two compounds were submitted for filing as 
CSIR - Indian Patent). In brief, the present study 
emphasizes, anticandidal efficacy of TMPMP 
and TMAP, and their impact on virulence factors 
of Candida spp including, acidic protease, 
neutral protease, alkaline protease, secreted 
aspartyl protease, lipase, phospholipase, 
keratinase, elastase and the antioxidant enzyme 
catalase.  
 
 
 
GLOBAL JOURNAL OF BIOCHEMISTRY 
 
 
75 
 
Global Journal of Biochemistry | Volume 2 | Issue 1 | March 2011  
 www.simplex-academic-publishers.com 
© 2011 Simplex Academic Publishers. All rights reserved. 
 
2. Experimental 
 
2.1. Chemicals 
Microbial growth media and 
supplements were purchased from Himedia, 
India. Chemicals for various buffers, reagents 
were purchased from SRL, India. All Solvents 
and acids were of AR grade purchased from 
Merck, India. 
 
2.2. Test organisms 
Antifungal efficacy of TMPMP and 
TMAP was evaluated using of 17 strains of 
Candida spp, including Type and clinical strains. 
Clinical isolates of Candida species were 
obtained from hospitals and characterized by 
growth in selective media, germ tube, and gram 
staining techniques [16, 17]. For clarity of 
presentation results of C.albicans SRM0510 
(clinical isolate) was alone discussed in detail.  
 
2.3. Determination of Minimum Inhibitory 
Concentration of TMPMP and TMAP 
Minimum Inhibitory Concentration 
(MIC) of TMPMP and TMAP for Candida spp. 
was determined by broth microdilution 
technique M27-A as recommended by the 
NCCLS.  
 
2.4. Effect of drugs on virulence factors and 
enzymes 
Effect of TMPMP and TMAP on 
virulence factors of C.albicans were evaluated at 
their sub-lethal concentration.  
 
2.5. Acidic Protease Assay (ACP) 
Acidic Protease activity of C.albicans 
of control and drug treated experiments was 
carried out using the protocols of Nelson and 
Young [18]. The assay mixture consists of 500 
µl of 0.1M citrate buffer, 400 µl hemoglobin, 
and 100 µl of sample. Mixture was incubated at 
37ºC for 30 minutes subsequently; 1ml of TCA 
(Trichloroaceticacid) was added and centrifuged 
at 5000 RPM for 5 minutes. The supernatant was 
then read at 280 nm for determining acidic 
protease. 
 
2.6. Neutral Protease Assay (NuP) 
Neutral Protease activity of C.albicans 
of control and drug treated experiments was  
carried out using the protocols of Kray and 
Wildi, [19]. Assay mixture consists of 300 µl of 
phosphate buffer, 500 µl of casein, 200 µl of 
sample; mixture was incubated at 60ºC for 10 
minutes. After incubation, 1 ml of TCA was 
added and centrifuged at 5000 RPM for 15 
minutes. Supernatant was then estimated for 
protein [20].  
 
2.7. Alkaline Protease Assay (Alp) 
Alkaline Protease activity of C.albicans 
of control and drug treated experiments was 
carried out using the protocols of Gupta et al 
[21]. Assay mixture consists of 500 µl of casein 
and 500 µl of sample; mixture was then heated at 
60ºC for 20 minutes, 1 ml of TCA was added 
and centrifuged at 5000 RPM for 15 minutes. 
The supernatant was then estimated for protein 
content [20].  
 
2.8. Secreted Aspartyl Protease (SAP) 
Secreted Aspartyl Protease activity of 
C.albicans of control and drug treated 
experiments was carried out using the protocols 
of Mac Donalds and Odds [22]. The assay 
mixture consists of BSA (2%) in 50 mM sodium 
citrate buffer, 200 µl of sample; mixture was 
then incubated at 37ºC for 30 minutes. After 
incubation, 200 µl of 2 M perchloric acid was 
added and incubated in ice for 15 minutes, 
centrifuged at 14000 RPM for 15 minutes. The 
culture supernatant was then read at 280 nm.  
 
Enzyme activity  
= (Test OD  Control OD×1000)  
(Volume of enzyme × incubation time × Mol.wt 
of Tyrosine) 
 
(1 unit of enzyme activity was defined 
as an amount of enzyme that liberates 1 µm 
tyrosine from substrate BSA/ml of enzyme under 
assay condition). 
 
2.9. Lipase assay 
Lipase activity of C.albicans of control 
and drug treated experiments was carried out 
using the protocols of Xu et al [23]. Assay 
mixture consists of 2 ml of 3% polyvinyl alcohol 
(PVA)/olive oil (3:1) and 0.025 M phosphate 
buffer (pH 7.5) in 200 µl of sample, incubated 
for 15 minutes at 40ºC. The reaction was stopped 
by the addition of 7.5 ml 95% ethanol. Fatty acid 
liberated was titrated with standard 0.05 M 
NaOH in the presence of phenolphthalein as 
indicator. One unit of lipase activity was defined 
as the amount of enzyme that produced 1 µmole 
of fatty acid per minute under the assay 
conditions described. 
 
Lipase activity  
= (Volume of NaOH consumed × Normality of 
NaOH) / Time of incubation 
 
Volume of NaOH consumed = Difference (Test- 
Control) 
 
2.10. Phospholipase assay 
Phospholipase activity of C.albicans of 
control and drug treated experiments was carried 
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out using the protocols of Leidich et al [24]. 
Briefly, assay mixture consists of 1ml of sample, 
1 ml of 60% perchloroacetic acid and heated in a 
sand bath at 200ºC until the solution turns 
colourless. Subsequently, one ml of 60% 
perchloroacetic acid was added and the final 
volume was made to 9.1 ml using distilled water, 
to this 0.5 ml of molybdate II reagent and 0.4 ml 
ANSA reagent mixture of was added. The tubes 
were shaken well and heated in a boiling water 
bath for 8 minutes exactly. The blue colour 
developed was read spectrophotometerically at 
680 nm. 
 
2.11. Keratinase Assay 
Keratinase activity of C.albicans of 
control and drug treated experiments was carried 
out using the protocols of Brandelli [25]. The 
assay mixture consists of 100 µl of sample, 800 
µl of Tris and 200 µl of azokeratin. The reaction 
mixture was incubated at 40ºC for 15 minutes in 
water bath and subsequently 1 ml of TCA was 
added. In case of control, TCA (1 ml) was added 
prior to incubation. The assay mixtures were 
then centrifuged at 5000 RPM for 15 minutes. 
To the supernatant, 5 ml of sodium carbonate 
was added, incubated for 10 minutes. 
Subsequently, 1 ml of Folins reagent was 
added, incubated for 30 - 60 minutes, and 
measured the optical density at 660 nm. 
 
2.12. Elastase activity 
Elastase activity of C.albicans of 
control and drug treated experiments was carried 
out using the protocols of Mc Iver et al [26]. 
Briefly, 200 µl of substrate (SANA- N-succ-
(Ala)3-p-nitroanilide) in 1.2 ml of 1 mM Tris 
buffer (pH 8) was added to 100 µl of sample. 
The optical density was measured at 410 nm. In 
control experiments distilled water was added 
instead of sample. 
 
2.13. Catalase activity 
Catalase activity of C.albicans of 
control and drug treated experiments was carried 
out using the protocols of Aebi et al [27]. 
Briefly, 0.56 µl of hydrogen peroxide (AR 
grade, SRL, India) was added to 10 ml of 0.1 M 
Potassium phosphate buffer. To 1ml of the 
above-mentioned hydrogen peroxide-buffer 
solution, 2ml of distilled water, and 100 µl of 
sample were added.  
 
Enzyme unit/ml  
= Absorbance at 240 nm×100 
43.6× ml of enzyme × ml of the reaction mixture 
 
2.14. Statistical Analysis 
All experiments were carried out in 
triplicates. Results were carefully analyzed and 
statistically defined using ANOVA. 
 
3. Results and Discussion 
 
In our preliminary studies we reported, 
the crude methanolic extracts of A.calamus 
rhizome and the unidentified active fractions 
exhibited antidermatophytic as well as 
anticandidal properties [16,17]. From our 
continuous studies, we received two novel 
terpenoids of A.calamus. These two terpenoids 
are not reported elsewhere and the patent 
protection was made accordingly. The present 
study emphasizes the antifungal efficacy of those 
two novel terpenoids and further demonstrates 
the mode of action of these two drugs by 
assessing their effect on virulence factors of the 
chosen pathogen. Both clinical and type strains 
of C.albicans (9 strains), C. tropicalis (3 strains), 
C. dublinensis (1 strains), C. sake (2 strains), C. 
boidnii (2 strains) were chosen for the present 
study. However for better understanding, results 
of C.albicans SRM 0510, alone was presented 
and discussed.  The antifungal efficacy of acidic 
terpenoids extracted from natural sources, 
reported by Onishi et al [28] and Inouye et al 
[15] reported the antidermatophytic efficacy. 
 
3.1. Antifungal efficacy of TMPMP and TMAP 
Minimum Inhibitory Concentration 
(MIC) of the chosen drugs for C.albicans SRM 
5210, was the lowest drug concentration 
required to cause a prominent reduction in 
growth. MIC of TMPMP and TMAP was  
identified as 1.0 and 1.5 µg/ml respectively. 
Similar to our findings, Onishi et al [28] reported 
new MIC in the range of 0.25 to 1 µg/ml for 
acidic terpenoids extracted from natural sources. 
The MIC of standard drug was estimated as 0.7 
µg/ml. 
 
3.2. Virulence factors 
Pathogenicity greatly depends on 
complex array of microorganism-related putative 
virulence factors [29, 30]. C.albicans expresses 
several virulence factors contributing  to their 
pathogenicity, which includes,  yeast  to  
mycelium transition, antigenic variability,  
phenotypic switching, adhesion to host cells 
surface hydrophobicity, molecular mimicry and 
production of extracellular enzymes. Most of the 
biological functions related to pathogenesity and 
virulence resides in fungal cell wall [29, 30]. 
Expression of virulence factors may be 
associated with specific characteristics of 
Candida isolates. The role of virulence factors in 
establishing the infections was vital in disease 
manifestations. Figure 1 illustrates the overall 
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scenario of the role of virulence factors during 
different stages of infection caused by Candida 
spp.  
The effect of TMPMP and TMAP on 
the virulence factors of C.albicans SRM 0510 
was evaluated at their respective sub-lethal 
levels. It has been evidenced from the 
experimental results that C.albicans produce 
enzymes responsible for their virulence within a 
limited time of 48 hours. Secreted aspartyl 
proteases, in general, are capable of degrading 
epithelial and mucosal barrier proteins such as 
collagen, keratin and mucin, cloning and 
disruption of genes for these enzymes have 
shown their involvement in virulence of Candida 
species [31-33, 24, 34]. About 35 and 45% 
reduction in SAP activity were observed upon 
treatment with TMPMP and TMAP respectively 
(in comparison with control as 100%) (Figure 
2a). Similarly, neutral, acidic and alkaline 
proteases are pivotal for establishing infections, 
treating C.albicans with TMPMP and TMAP 
exhibited reduced level (50%) of expression of 
said enzymes. Morschhauser et al [35] reported 
that acid proteases might be of importance in 
C.albicans penetration into deep organs. About 
0.2 enzymes units/ml of acid and neutral 
proteases was observed in control cells and upon 
treatment 50% reduction in activity in TMPMP 
and TMAP treated cells respectively was 
observed (Figure 2a). With regard to alkaline 
proteases, control cells showed 0.6 units/ml; 
whereas 15 and 11% reduction in activity were 
observed with TMPMP and TMAP treated cells 
respectively (Figure 2a).  The values observed 
were on par with the results obtained with 
standard drug. 
Since skin is composed primarily of 
lipids, lipases and phospholipase are prime 
virulence factors of skin colonising pathogens. 
Phospholipases are the most likely to contribute 
to pathogenicity of Candida species, by 
damaging host cell membranes, and thereby 
facilitates invasion into host tissues [32]. In 
control cells phospholipases content was 0.4 
units/ml and upon treatment with TMPMP and 
TMAP, the content reduced by 75%. Similarly, 
lipases activity was 0.4 units/ml in control cells 
and on treating with TMPMP and TMAP, the 
reduction observed was 75% (Figure 2b). In 
addition, keratinase and elastase are the two 
important virulence factors required for the 
colonization of skin. In C. albicans treated with 
TMAMP and TMAP, keratinase activity was 
reduced by 35-46% and 28% reduction in 
elastase activity (Figure 2c). Results on 
reduction in enzyme activities were on par with 
the standard drug. An overview of effect of 
TMPMP and TMAP on the virulence factors 
suggests, there was a reduction of enzymatic 
virulence activity.  
 
 
Figure 1. Role of virulence factors in pathogenesis of Candida spp. 
 
Virulence factors
GLOBAL JOURNAL OF BIOCHEMISTRY 
 
 
78 
 
Global Journal of Biochemistry | Volume 2 | Issue 1 | March 2011  
 www.simplex-academic-publishers.com 
© 2011 Simplex Academic Publishers. All rights reserved. 
As far as the antioxidant enzyme 
catalase was concerned, in contradiction to 
enzymatic virulence factor content, in the 
present study, there was an increase in the 
expression of catalase in C.albicans treated with 
TMPMP and TMAP. Catalase content in control 
experiments was 10 units/ml, whereas an 
increase of 140, 160% was observed in TMPMP, 
TMAP treated cells (Figure 2d). Miyasaka et al 
[36] reported that extracellular catalase activity 
could be detected in yeast in oxidative stress 
conditions. Further, various authors also report 
that the effects of stresses on Candida spp are 
transduced through a variety of membrane 
receptors and elicit responses through conserved 
signaling pathways, of which most important 
being the MAP kinase (MAPK) signal 
transduction network [37]. Two important 
components of the MAPK network are high-
osmolarity glycerol (HOG; Hog1p) pathway and 
protein kinase C cell wall integrity (Mkc1p) 
pathway, which respond to oxidative, osmotic 
and heavy metal  stress [38,39]. The response to 
oxidative stress transduced via both Mkc1p and 
Hog1p and involved in the increased expression 
of antioxidants such as catalase, superoxide 
dismutase and glutathione [40].  
  
 
 
4. Conclusions 
 
Invitro antifungal efficacy of TMPMP 
and TMAP was evaluated using C.albicans 
SRM0510. The antifungal efficacy of TMPMP 
and TMAP was comparable with that of standard 
drugs. Studies on the virulence factors showed a 
reduced extracellular enzyme production upon 
treatment with TMPMP and TMAP. While in the 
case of antioxidant enzymes there was an 
enhanced production. It is evident from the 
studies that the active components TMPMP and 
TMAP can combat fungal infections in all stages 
of infections, as they were pleomorphic in 
function.  
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